SNPs in PI3K-PTEN-mTOR and brain metastases in NSCLC-letter

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3623-3624

  Avan, Abolfazl ^a   Maftouh, Mina ^a   Avan, Amir ^a,b   Tibaldi, Carmelo ^c   Zucali, Paolo A ^d   Giovannetti, Elisa ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Division of Oncology   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

BRAIN METASTASIS; CANCER STAGING; ETHNICITY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG NON SMALL CELL CANCER; MAMMALIAN TARGET OF RAPAMYCIN GENE; PHOSPHATIDYLINOSITOL 3 KINASE GENE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; RNA SPLICING; SAMPLE SIZE; SINGLE NUCLEOTIDE POLYMORPHISM; BRAIN TUMOR; FEMALE; GENETICS; LUNG TUMOR; MALE; NON SMALL CELL LUNG CANCER; SECONDARY;

BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 84903845199     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-3256     Document Type: Letter

References (5)

1. Li Q, Yang J, Yu Q, Wu H, Liu B, Xiong H, et al. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer. Clin Cancer Res 2013;19: 6252-60.
2. Maitland ML, Ratain MJ, Cox NJ. Interpreting P values in pharmacogenetic studies: a call for process and perspective. J Clin Oncol 2007;25: 4513-5.
3. Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010;9: 581-93.
4. + NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): potential implications for management. J Clin Oncol 2012; 30(suppl): 7600.
5. Yang CH, Cheng YH, Chuang LY, Chang HW. Drug-SNPing: anintegrated drug-based, protein interaction-based tagSNP-based pharmacogenomics platform for SNP genotyping. Bioinformatics 2013;29: 758-64.